MannKind Corp. said it expects to meet with regulators next week about proposed late-stage trials for its inhaled insulin drug Afrezza, but its lack of details worried some investors. Analysts said Wall Street may have been hoping for more specifics about the development of Afrezza, and added that MannKind is low on cash. Late Thursday the company reported its cash, cash equivalents and marketable securities at June 30 totaled $25.3 million, down from $70.4 million at Dec. 31. In a conference call late Thursday to discuss quarterly results, President and Chief Operating Officer Hakan Edstrom said the company will meet with Food and Drug Administration officials on Wednesday.
